Clinical trials
Interstitial Lung Disease clinical trials
Below are recruiting interstitial lung disease clinical trials, each written for real people, not researchers. We’re tracking 195 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05746039RecruitingPhase 1/Phase 2
Testing semaglutide for advanced lung disease
This study checks whether semaglutide is safe and feasible for people with advanced lung diseases and higher body weight. It may help by testing a structured treatment approach, but it includes several health and safety limits.
Philadelphia, PennsylvaniaAges 18–80 - NCT05785065RecruitingPhase 2
Mycophenolate for early lung scarring in systemic sclerosis
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
Montreal, QuebecAges 18 years+ - NCT05819385Recruiting
Study of lung scarring in immune diseases
This is an observational (non-treatment) study that collects information about how interstitial lung disease (lung scarring) happens in people with certain autoimmune or immune-related conditions. It uses patient interviews or existing medical records to better understand the pattern and causes, which may help future care.
Mexico CityAges 18 years+ - NCT05854563Recruiting
Study using collected cough samples to learn about lung disease
This trial looks at “cough capture” samples to better understand what is happening in the lungs. You might be eligible if you’re having a bronchoscopy for medical reasons and don’t already have lung cancer.
The Bronx, New YorkAges 21 years+ - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Phoenix, ArizonaAges 18 years+ - NCT05892614RecruitingPhase 2
Efzofitimod for early systemic sclerosis lung scarring
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Los Angeles, CaliforniaAges 18 years+ - NCT05947422Recruiting
CT scan test for lung scarring assessment
This trial tests how well a CT scan and lung function tests can measure interstitial lung disease (ILD), which is long-term scarring or inflammation in the lungs. It may help doctors use these images and tests more accurately to track ILD.
Asyut, Asyut GovernorateAges 18–90 - NCT05986318RecruitingPhase 2
Reducing breathing issues from lung radiation in people with ILD
This trial tests whether a combination of two medications (dexamethasone and N-acetyl cysteine) can reduce breathing problems caused by radiation to lung tumors in patients who have both lung cancer and fibrotic interstitial lung disease (ILD). It aims to find a better way to manage side effects from radiation.
Vancouver, British ColumbiaAges 18 years+ - NCT06036719Recruiting
Lung scarring study from childhood to old age
This trial looks at different types of lung scarring (called interstitial lung disease) to better understand the condition across all ages. It also includes family members of people with certain genetic mutations that affect the lungs.
Paris, Île-de-France RegionAges Any age - NCT06046547Recruiting
Palliative care learning for lung rehab patients
This trial tests adding palliative care education to pulmonary rehabilitation for people with COPD or ILD and their caregivers. It aims to see if this helps improve symptom management and quality of life.
AveiroAges 18 years+ - NCT06053164RecruitingPhase 2
Portable oxygen for activity in mild-to-moderate lung disease
This study is testing whether using portable oxygen during physical activity can help people with mild-to-moderate interstitial lung disease feel better and be more active. It is for people whose oxygen levels drop during exercise but are normal at rest.
Edmonton, AlbertaAges 18–85 - NCT06068647Recruiting
Ultrasound and breathing tests for lung disease patients
This study uses ultrasound and sensors to monitor lung health in people with certain lung conditions, including those that cause scarring or breathing problems. It aims to find better ways to track lung disease, which could help manage your condition more effectively.
RomeAges 18 years+ - NCT06087692Recruiting
Video game therapy for lung disease patients
This trial tests whether playing interactive video games can help people with interstitial lung disease (a type of chronic lung condition). It aims to improve breathing and daily function through fun, guided exercises.
IstanbulAges 40–65 - NCT06122233Recruiting
Digital self-management for fibrotic lung disease
This trial tests whether a digital self-management program (using a smartphone or tablet) helps people with fibrotic interstitial lung disease better manage their symptoms and quality of life. If you have this lung condition and can use a mobile device, this study could offer you extra support at home.
Sydney, New South WalesAges 18 years+ - NCT06195072RecruitingPhase 2
Platform study for scleroderma with lung disease
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Birmingham, AlabamaAges 18 years+ - NCT06235645Recruiting
Detecting lung disease in rheumatoid arthritis with ultrasound
This study tests if a lung ultrasound can detect early signs of lung disease in people with rheumatoid arthritis. It may help you if you have certain risk factors, like being male, older, or a smoker.
ToursAges 18 years+ - NCT06247397Recruiting
High-flow therapy for long-term oxygen users
This trial tests if adding high-flow oxygen therapy to your usual long-term oxygen therapy can help you breathe better. It is for people with COPD or ILD who use oxygen at home for at least 15 hours a day.
Karlskrona, Blekinge CountyAges 18 years+ - NCT06297096RecruitingPhase 3
Testing a two-drug combo for lung scarring in scleroderma
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
Warsaw, Masovian VoivodeshipAges 18–74 - NCT06304207Recruiting
Study comparing remote vs in-person exercise for lung disease
This study tests whether a telehealth exercise program works as well as in-person sessions for people with chronic lung disease. You may join if you recently finished rehab for your lung condition and can walk with or without help.
Charlestown, MassachusettsAges 40 years+ - NCT06317831Recruiting
Let's get functional: function in interstitial lung disease
This trial tests a program to help people with interstitial lung disease improve their daily function and activity. It is for Portuguese speakers with any type of ILD who are otherwise stable.
AveiroAges 18 years+ - NCT06326957Recruiting
Online program for chronic breathlessness
This trial tests an internet-based self-guided program to help adults with chronic breathlessness. It is designed for people who still feel short of breath despite treatment for conditions like COPD, lung disease, or cancer.
LondonAges 18–110 - NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Birmingham, AlabamaAges 18 years+ - NCT06397677Recruiting
Study of Progressive RA Interstitial Lung Disease
This study is looking at people with rheumatoid arthritis (RA) who also have interstitial lung disease (ILD), a condition that causes scarring in the lungs. It aims to understand how the disease changes over time by using imaging and blood tests, without providing any new treatments right now.
San Francisco, CaliforniaAges 18–90 - NCT06440746RecruitingPhase 2/Phase 3
Testing olokizumab for progressive lung scarring diseases
This trial tests a drug called olokizumab to see if it can slow down worsening lung scarring (fibrosis) in people with certain types of progressive interstitial lung diseases. It's for patients whose lung function has declined despite current treatments.
BarnaulAges 18 years+
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for interstitial lung disease?
- Yes. Clin2 currently lists 195 recruiting interstitial lung disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a interstitial lung disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a interstitial lung disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.